All In Biotech

Drug Trial Radar · NCT02331823

Research on New Regimens for Retreatment Pulmonary Tuberculosis

New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Jan 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 864 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

864

Planned (sponsor's estimate)

Start

Jun 2013

Primary completion

Dec 2015

Study completion Dec 2016

Sponsor

Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Center for Disease Control and Prevention; Jiangsu Province Centers for Disease Control and Prevention; Zhejiang University; Centers for Disease Control and Prevention
First posted
Jan 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, prospective study is performed to investigate the efficacy of new short-course regimen for retreatment pulmonary tuberculosis patients. To obtain optimized short-course regimen, decrease treatment cost and improve success rate.

Conditions

  • Reinfection Pulmonary Tuberculosis

Interventions

  • Isoniazid Aminosalicylate TabletsDrug

    a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.

  • Streptomycin injectableDrug

    standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. success rateTime frame: for arm A,the point is 5 month after treatment. For arm B,the time point is at the end of the 8 or 9 month's treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.